Praxis Precision Medicines
PRAX
162 hedge funds and large institutions have $1.67B invested in Praxis Precision Medicines in 2024 Q4 according to their latest regulatory filings, with 38 funds opening new positions, 56 increasing their positions, 52 reducing their positions, and 10 closing their positions.
280% more first-time investments, than exits
New positions opened: 38 | Existing positions closed: 10
155% more call options, than puts
Call options by funds: $74.7M | Put options by funds: $29.3M
53% more capital invested
Capital invested by funds: $1.09B → $1.67B (+$580M)
40% more funds holding in top 10
Funds holding in top 10: 5 → 7 (+2)
21% more funds holding
Funds holding: 134 → 162 (+28)
10.29% more ownership
Funds ownership: 106.24% → 116.53% (+10%)
8% more repeat investments, than reductions
Existing positions increased: 56 | Existing positions reduced: 52
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
+$78.4M |
| 2 |
CAM
Cormorant Asset Management
Boston,
Massachusetts
|
+$59.6M |
| 3 |
Assenagon Asset Management
Senningerberg,
Luxembourg
|
+$39.7M |
| 4 |
Janus Henderson Group
London,
|
+$29.4M |
| 5 |
VA
VR Adviser
New York
|
+$20.5M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Point72 Asset Management
Stamford,
Connecticut
|
-$37M |
| 2 |
Adage Capital Partners
Boston,
Massachusetts
|
-$18M |
| 3 |
5VM
5AM Venture Management
San Francisco,
California
|
-$12.3M |
| 4 |
Wellington Management Group
Boston,
Massachusetts
|
-$11.3M |
| 5 |
Marshall Wace
London,
United Kingdom
|
-$8.09M |
PRAX Hedge Fund Activity: Q4 2024 in Review
162 of the 7,607 institutional investors tracked by Wall St. Rank reported a position in Praxis Precision Medicines (PRAX) for Q4 2024, worth a combined $1.67B — up 53% from $1.09B a quarter earlier.
Buyers outnumbered sellers: 38 funds opened new PRAX positions and 10 closed out — a net gain of 28 holders — while 56 added to existing stakes and 52 trimmed.
The largest buyer was Morgan Stanley, adding an estimated $78.4M. The largest seller was Point72 Asset Management, cutting an estimated $37M.
- 162 institutional investors held Praxis Precision Medicines (PRAX) as of Q4 2024, up from 134 in Q3 2024.
- Funds reported $1.67B of Praxis Precision Medicines stock for Q4 2024, up 53% quarter-over-quarter.
- 38 funds opened new Praxis Precision Medicines positions in Q4 2024 and 10 closed out, a net change of +28 holders.
- The largest Praxis Precision Medicines buyer in Q4 2024 was Morgan Stanley, an estimated $78.4M added.
- The largest Praxis Precision Medicines seller in Q4 2024 was Point72 Asset Management, an estimated $37M sold.
Based on aggregated 13F filings for Q4 2024.